pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 14·1 min read
save

Novo Nordisk rebrands as 'Novo' and launches new culture strategy after recent setbacks

Sep 14, 2026·read at Endpoints ↗Neutral

Novo Nordisk announced it will drop "Nordisk" from its public brand, opting to be known simply as "Novo" starting Monday.

The name change is part of a broader cultural overhaul aimed at revitalizing the company's internal environment after a series of challenges earlier in the year.

CEO Mike Doustdar said the new branding reflects a focus on agility and a refreshed corporate identity, though no specific product or financial impacts were detailed.

The move follows recent setbacks, but the company hopes the streamlined name and culture program will improve morale and stakeholder perception.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Novo Nordisk shortens its name in brand and culture reboot”

read at Endpoints ↗
88 words · retrieved Sep 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO6Novo Nordisk Inc3

related stories

  • May 7Seaport’s IPO adventure, obesity pill battles, and Makary’s troublesSTAT
  • May 7STAT+: FDA revisits a rare cancer treatment it rejected a few months agoSTAT
  • May 7STAT+: FDA to reconsider treatment for rare cancer after its surprise rejectionSTAT
  • May 7STAT+: Next-gen Duchenne drug from Entrada disappointsSTAT
  • May 7STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1BSTAT